Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD8154 in mild allergic asthma
NCT04187508Phase 2Withdrawn
- Sponsor
- AstraZeneca
- Start
- Feb 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic asthma comparing AZD8154 with Placebo (2 arms). Primary endpoints: Maximal percentage decrease in forced expiratory volume in 1 second (FEV1) 3-7 hours post-allergen challenge at Day 9 and Area under the curve (AUC) of time adjusted percent decrease in FEV1 in late asthmatic response (LAR) 3-7hr at Day 9. Planned start Feb 2020; status: withdrawn.
02
Drugs
AZD8154
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT04187508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04187508.